Wainzua (eplontersen)
Additional monitoring
- Region
- 🇪🇺 EU
- Active substance
- eplontersen
- Company
- AstraZeneca AB
- Status
- Authorised
- Therapeutic area
- Amyloid Neuropathies, Familial
- CHMP opinion
- Thu 17 Oct 2024
- EU approval
- Thu 06 Mar 2025
- Designations
- Additional monitoring
- Application
- EMEA/H/C/006295
- ATC
- N07XX21
- Official record
- www.ema.europa.eu
Indication
Treatment of hereditary transthyretin-mediated amyloidosis (ATTRv) in adult patients with stage 1 or stage 2 polyneuropathy.
Regulatory milestones
No milestones recorded in the last year.
Follow Wainzua
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.